Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01AYF
|
||||
| Former ID |
DIB012432
|
||||
| Drug Name |
ND-1.1
|
||||
| Synonyms |
Avian influenza vaccine, West Coast Biologicals; Ad-HA-dsRNA; H5N1 avian influenza vaccine (oral, adenoviral vector,dsRNA adjuvant), Vaxart
|
||||
| Drug Type |
Vaccine
|
||||
| Indication | Influenza virus [ICD10:J11.1] | Phase 1 | [1] | ||
| Company |
Glaxosmithkline; novavax; vaxart
|
||||
| Target and Pathway | |||||
| Target(s) | Hemagglutinin | Target Info | [2] | ||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01698060) Immunogenicity of ND1.1 by Delivery Directly to the Ileum. U.S. National Institutes of Health. | ||||
| REF 2 | An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.